Quality of Life Improvements with Biologic Initiation Among Subspecialist-Treated US Patients with Severe Asthma

References

• Lugogo N, Judson E, Haight E, et al. Severe asthma exacerbation rates are increased among female, Black, Hispanic, and younger adult patients: results from the US CHRONICLE study. J Asthma. 2022;59(12):2495–2508. doi:10.1080/02770903.2021.2018701
   PubMed Web of Science ®Google Scholar
• Siddiqui S, Denlinger LC, Fowler SJ, et al. Unmet needs in severe asthma subtyping and precision medicine trials. Bridging clinical and patient perspectives. Am J Respir Crit Care Med. 2019;199(7):823–829. doi:10.1164/rccm.201809-1817PP
   PubMed Web of Science ®Google Scholar
• McDonald VM, Hiles SA, Jones KA, Clark VL, Yorke J. Health-related quality of life burden in severe asthma. Med J Aust. 2018;209(S2):S28–S33. doi:10.5694/mja18.00207
   PubMed Web of Science ®Google Scholar
• Czira A, Turner M, Martin A, et al. A systematic literature review of burden of illness in adults with uncontrolled moderate/severe asthma. Respir Med. 2022;191:106670. doi:10.1016/j.rmed.2021.106670
   PubMed Web of Science ®Google Scholar
• McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am J Respir Crit Care Med. 2019;199(4):433–445. doi:10.1164/rccm.201810-1944CI
   PubMed Web of Science ®Google Scholar
• Clark VL, Gibson PG, McDonald VM. What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance. ERJ Open Res. 2021;7(1):00497–2020. doi:10.1183/23120541.00497-2020
   PubMedGoogle Scholar
• Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;2014(1):Cd003559. doi:10.1002/14651858.CD003559.pub4
   PubMedGoogle Scholar
• Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K. ‘Real‐life’effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2016;71(5):593–610. doi:10.1111/all.12815
   PubMed Web of Science ®Google Scholar
• Harrison TW, Chanez P, Menzella F, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, Phase 3b trial. Lancet Respir Med. 2021;9(3):260–274. doi:10.1016/S2213-2600(20)30414-8
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, Hearn AP, Jackson DJ. A pragmatic guide to choosing biologic therapies in severe asthma. Breathe. 2021;17(4):210144. doi:10.1183/20734735.0144-2021
   Web of Science ®Google Scholar
• Israel E, Canonica GW, Brusselle G, et al. Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review. J Asthma. 2022;59(11):2201–2217. doi:10.1080/02770903.2021.2008431
   PubMed Web of Science ®Google Scholar
• Corren J, Castro M, Chanez P, et al. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol. 2019;122(1):41–49.e42. doi:10.1016/j.anai.2018.08.005
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. doi:10.1016/S2213-2600(17)30125-X
   PubMed Web of Science ®Google Scholar
• Kelmenson DA, Kelly VJ, Winkler T, et al. The effect of omalizumab on ventilation and perfusion in adults with allergic asthma. Am J Nucl Med Mol Imaging. 2013;3(4):350.
   PubMedGoogle Scholar
• Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract. 2019;7(1):156–164. e151. doi:10.1016/j.jaip.2018.04.043
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Chipps BE, Moore WC, et al. The CHRONICLE study of US adults with subspecialist-treated severe asthma: objectives, design, and initial results. Pragmat Obs Res. 2020;11:77–90. doi:10.2147/POR.S251120
   PubMed Web of Science ®Google Scholar
• Nelsen LM, Kimel M, Murray LT, et al. Qualitative evaluation of the St George’s Respiratory Questionnaire in patients with severe asthma. Respir Med. 2017;126:32–38. doi:10.1016/j.rmed.2017.02.021
   PubMed Web of Science ®Google Scholar
• Jones PW. St. George’s Respiratory Questionnaire: MCID. COPD. 2005;2(1):75–79. doi:10.1081/COPD-200050513
   PubMedGoogle Scholar
• Soong W, Chipps BE, O’Quinn S, et al. Health-related quality of life and productivity among us patients with severe asthma. J Asthma Allergy. 2021;14:713–725. doi:10.2147/JAA.S305513
   PubMed Web of Science ®Google Scholar
• Alhossan A, Lee CS, MacDonald K, Abraham I. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract. 2017;5(5):1362–1370. e1362. doi:10.1016/j.jaip.2017.02.002
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, Hearn AP, Dhariwal J, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159(2):496–506. doi:10.1016/j.chest.2020.08.2083
   PubMed Web of Science ®Google Scholar
• Nelsen LM, Cockle SM, Gunsoy NB, et al. Impact of exacerbations on St George’s Respiratory Questionnaire score in patients with severe asthma: post hoc analyses of two clinical trials and an observational study. J Asthma. 2020;57(9):1006–1016. doi:10.1080/02770903.2019.1630640
   PubMed Web of Science ®Google Scholar
• Apps LD, Chantrell S, Majd S, et al. Enabling adults with severe asthma to exercise: a qualitative examination of the challenges for patients and healthcare professionals. J Allergy Clin Immunol Pract. 2023;11(11):3435–3444.e2. doi:10.1016/j.jaip.2023.07.008
   PubMed Web of Science ®Google Scholar
• Kraft M, Corren J, Ambrose C, et al. Clinically meaningful improvements in St George’s Respiratory Questionnaire score with tezepelumab versus placebo in patients with severe, uncontrolled asthma: results from the phase 3 NAVIGATOR study. Am J Respir Crit Care Med. 2022;1(205):A2360–A2360.
   Google Scholar
• Kavanagh J, Jackson DJ, Kent BD. Sleep and asthma. Curr Opin Pulm Med. 2018;24(6):569–573. doi:10.1097/MCP.0000000000000526
   PubMed Web of Science ®Google Scholar
• Stubbs MA, Clark VL, Gibson PG, Yorke J, McDonald VM. Associations of symptoms of anxiety and depression with health-status, asthma control, dyspnoea, dysfunction breathing and obesity in people with severe asthma. Respir Res. 2022;23(1):341. doi:10.1186/s12931-022-02266-5
   PubMed Web of Science ®Google Scholar
• Song HJ, Blake KV, Wilson DL, Winterstein AG, Park H. Health-related quality of life and health utilities of mild, moderate, and severe asthma: evidence from the medical expenditure panel survey. J Asthma Allergy. 2021;929–941. doi:10.2147/JAA.S316278
   PubMed Web of Science ®Google Scholar
• Wilson SR, Strub P, Buist AS, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med. 2010;181(6):566–577. doi:10.1164/rccm.200906-0907OC
   PubMed Web of Science ®Google Scholar
• Hyland ME, Whalley B, Jones RC, Masoli M. A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales. Qual Life Res. 2015;24(3):631–639. doi:10.1007/s11136-014-0801-x
   PubMed Web of Science ®Google Scholar